We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Bioatla Inc
7 own
5 watching
Current Price
$0
$-0.05
(-1.26%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
176.73M
52-Week High
12.15
52-Week Low
2.235
Average Volume
0.1M
Dividend Yield
--
P/E Ratio
--
Market Capitalization176.73M52-Week High12.1552-Week Low2.235Average Volume0.1MDividend Yield--P/E Ratio--What does the Bioatla Inc do?
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Read More
How much money does Bioatla Inc make?
News & Events about Bioatla Inc.
Globe Newswire
2 months ago
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call...
Globe Newswire
3 months ago
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be...
Globe Newswire
3 months ago
Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage ...
Globe Newswire
4 months ago
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is...
Globe Newswire
5 months ago
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Companys management will ...
Frequently Asked Questions
Frequently Asked Questions
What is Bioatla Inc share price today?
Can Indians buy Bioatla Inc shares?
How can I buy Bioatla Inc shares from India?
Can Fractional shares of Bioatla Inc be purchased?
What are the documents required to start investing in Bioatla Inc stocks?
What is today’s traded volume of Bioatla Inc?
What is today’s market capitalisation of Bioatla Inc?
What is the 52-Week High and Low Range of Bioatla Inc?
What percentage is Bioatla Inc down from its 52-Week High?
What percentage is Bioatla Inc up from its 52-Week Low?
Current Price
$0
$-0.05
(-1.26%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.